Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin renal glucose reabsorption kinetics
NCT01867307Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Jun 2013; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01867307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867307.